AminoRT
A synthetic triple GIP / GLP-1 / glucagon receptor agonist (research code LY3437943), characterized in preclinical metabolic research.
Customers also frequently order with
Verified, not just claimed
Plenty of sellers say "tested." Every Steadfast batch ships with a Certificate of Analysis you can actually check against the lot in your hand.
| Steadfast | Typical unverified seller | |
|---|---|---|
| Certificate of Analysis per batch | Included | Rarely provided |
| Purity independently verified by HPLC | Every lot | Unconfirmed |
| Cold-chain shipping | Standard | Not guaranteed |
| Lot-matched documentation on request | Yes | Rarely available |
Comparison describes documentation and handling practices, not product safety or efficacy claims. For laboratory research use only.
What research has studied about Retatrutide
Retatrutide is a synthetic peptide that acts as an agonist at three metabolic hormone receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. It has been characterized in published preclinical pharmacology studies as a single-molecule “triagonist.”
In laboratory and animal-model research, retatrutide has been studied for how simultaneous activity at these three receptors influences metabolic parameters such as glucose handling and energy balance. These are in-vitro and rodent-model observations reported in the literature; nothing here describes use in humans. Our research blog covers what published research says about retatrutide in more depth, including its amino-acid structure and the trial record behind it.
Certificate of Analysis
A representative third-party certificate for Retatrutide. Every batch ships with a lot-matched COA; contact us for the certificate on any other lot.
Specifications
| Compound | Retatrutide |
| Available sizes | 10 mg, 20 mg, 30 mg |
| Form | Lyophilized powder |
| Purity | Measured by HPLC; see the Certificate of Analysis for the lot |
| Storage | Store cold and away from light per your lab protocol |
| Intended use | Laboratory and research use only |
Research sources
- Coskun T, et al., "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist," Cell Metabolism 34(9):1234–1247 (2022). PMID 35985340
- Finan B, et al., "A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents," Nature Medicine 21(1):27–36 (2015). PMID 25485909
Frequently asked questions
What is retatrutide?
Retatrutide (research code LY3437943) is a synthetic peptide characterized in published preclinical studies as a triple agonist at the GIP, GLP-1, and glucagon receptors. Steadfast supplies it as a lyophilized research material for laboratory use only.
What has research studied about retatrutide?
Published preclinical work has characterized its activity at the three receptors in vitro and described effects on metabolic parameters in rodent models — laboratory and animal-model observations, not statements about human use.
Is it intended for human use?
No. It is a research chemical for in-vitro laboratory research only. It is not a drug or supplement and is not intended to diagnose, treat, cure, or prevent any disease.